Eisai files lenvatinib in rare thyroid indication
This article was originally published in Scrip
Executive Summary
Eisai has filed its novel targeted anticancer lenvatinib (E7080) for approval in the US, EU and Japan on the basis of its SELECT study in progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC), its first markets. The first submission was made in Japan in June, followed by the US and EU this month.